RxDoctor Payments Data

Candice Dean, DO

Internal Medicine · Longview, TXNPI 1174878540

Payments from drug & device makers

$1,428in general payments, 2019–2025

Across 112 payments — averaging $12.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$309
  • Pfizer$243
  • AstraZeneca$191
  • Johnson & Johnson$117
  • Sanofi-aventis U.S. LLC$114
  • Amgen$82
  • plus $373 from 12 others

What the payments were for

  • Food & beverage$1,41599%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,428 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$130,196
Medicare patients
481
Services billed
1,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin135$159,631
MounjaroTirzepatide129$139,524
OzempicSemaglutide114$138,045
EliquisApixaban93$124,814
TradjentaLinagliptin48$61,250
TrulicityDulaglutide39$45,762
JanuviaSitagliptin Phosphate37$45,341
LinzessLinaclotide23$33,452
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog63$32,732
MyrbetriqMirabegron28$31,349
XareltoRivaroxaban30$30,590
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$23,228
Tresiba Flextouch U-100Insulin Degludec38$19,500
Breo ElliptaFluticasone/Vilanterol25$15,971
SymbicortBudesonide/Formoterol Fumarate40$14,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$69$220,881183 claims
Lilly USA, LLCMounjaro, Trulicity$28$185,285168 claims
Novo NordiskOzempic, Novolog$309$142,363133 claims
PfizerEliquis$243$124,81493 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$15$50,04688 claims
MerckJanuvia$38$45,34137 claims
AbbVieLinzess, Synthroid$30$40,477111 claims
Johnson & JohnsonXarelto$117$30,59030 claims
AstraZenecaSymbicort$191$14,85940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →